VictORION-INCLUSION: Evaluating Inclisiran for Cholesterol Managment in Heart Disease

PHASE4Active, not recruitingINTERVENTIONAL
Enrollment

130

Participants

Timeline

Start Date

December 16, 2024

Primary Completion Date

September 30, 2026

Study Completion Date

December 31, 2026

Conditions
Atherosclerotic Cardiovascular Disease
Interventions
DRUG

Inclisiran

Inclisiran sodium 300 mg/1.5 ml (equivalent to 284 mg inclisiran liquid) in prefilled syringe (PFS).

Trial Locations (23)

19140

Temple University, Philadelphia

20814

JHU - Suburban Hospital, Bethesda

21044

Johns Hopkins, Columbia

27157

Wake Forest University, Winston-Salem

27514

University of North Carolina, Chapel Hill

27710

Duke University Medical Center, Durham

29403

Medical Univ. of South Carolina, Charleston

30141

Wellstar Paulding, Hiram

30324

Emory University, Atlanta

35205

Univ. of Alabama - Birmingham, Birmingham

52242

University of Iowa, Iowa City

53226

Medical College of Wisconsin, Milwaukee

55805

Essentia Health, Duluth

60612

Rush University, Chicago

63110

Washington University, St Louis

65212

University of Missouri, Columbia

68198

University of Nebraska, Omaha

76708

Baylor Scott & White - Waco, Waco

77030

Houston Methodist, Houston

84132

University of Utah, Salt Lake City

92868

Univ. of California - Irvine, Orange

94110

San Francisco General Hospital, San Francisco

08035

Heart House of NJ, Haddon Heights

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors
collaborator

Novartis Pharmaceuticals

INDUSTRY

lead

Duke University

OTHER